CME: C-reactive protein and ESR: What can one tell you that the other can't?

View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.